Experienced in Melanoma

Dr. Heather A. Wakelee

Oncology
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
Experienced in Melanoma
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Heather Wakelee is an Oncologist in Stanford, California. Dr. Wakelee is rated as an Experienced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.

Her clinical research consists of co-authoring 346 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Melanoma.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Pemetrexed Disodium, Vinorelbine Tartrate
Study Phase: Phase 3
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Biological, Drug
Study Drugs: VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab
Study Phase: Phase 1/Phase 2
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Drug, Other
Study Drugs: Methotrexate, Regorafenib
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tisotumab vedotin
Study Phase: Phase 2
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Enrollment Status: Completed
Publish Date: June 22, 2022
Intervention Type: Procedure
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Enrollment Status: Terminated
Publish Date: May 02, 2019
View 14 Less Clinical Trials

346 Total Publications

Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.
Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.
Journal: Annals of internal medicine
Published: December 15, 2025
Similar Doctors
Adil I. Daud
Elite in Melanoma
Dr. Adil I. Daud
Oncology | Hematology
Elite in Melanoma
Dr. Adil I. Daud
Oncology | Hematology

University Of California San Francisco

400 Parnassus Ave, Mcb300, 
San Francisco, CA 
 (27.6 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adil Daud is an Oncologist and a Hematologist in San Francisco, California. Dr. Daud is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Neuroendocrine Tumor.

Elite in Melanoma
Dr. Kevin Kim
Hematology | Oncology
Elite in Melanoma
Dr. Kevin Kim
Hematology | Oncology
2100 Webster St, 
San Francisco, CA 
 (28.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Kim is a Hematologist and an Oncologist in San Francisco, California. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Uveal Melanoma.

Alain P. Algazi
Elite in Melanoma
Dr. Alain P. Algazi
Hematology Oncology | Hematology | Oncology
Elite in Melanoma
Dr. Alain P. Algazi
Hematology Oncology | Hematology | Oncology

University Of California San Francisco

1600 Divisadero St, 
San Francisco, CA 
 (28.3 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alain Algazi is a Hematologist Oncology specialist and a Hematologist in San Francisco, California. Dr. Algazi is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, and Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wakelee's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile